December 1, 2022
Life Science Leader: Will The Finance And Funding Pendulum Swing Back To Black In 2023?
November 23, 2022
Psychiatric Times: Promising New Treatments For Postpartum Depression
October 28, 2022
Endpoints News: Peer Review
October 26, 2022
Fortune: CFO Daily Newsletter
October 24, 2022
BioWorld: Appointments And Advancements
October 24, 2022
Psychedelic Invest: Reunion Neuroscience Appoints Chief Financial Officer And Vice President, Medical Affairs
October 13, 2022
The Fly: Reunion CEO, CSO Talk Psychedelic Drug Development, Challenges, Opportunities, And More
September 30, 2022
Endpoints News: Peer Review
September 29, 2022
Drug Discovery & Development: An Inside Look At Reunion Neuroscience’s Psychedelic Strategy For Treating Depression
September 29, 2022
Psychedelic Invest: Reunion Neuroscience Inc. Appoints Greg Mayes As President And Chief Executive Officer
September 28, 2022
Seeking Alpha: Reunion Neuroscience Appoints Greg Mayes As President And CEO
September 28, 2022
Drug Discovery & Development: Reunion Neuroscience Names New CEO To Guide Development Of Psychedelic Depression Therapy
September 28, 2022
MarketWatch: Reunion Neuroscience Names Mayes As President, CEO
November 9, 2020
Lucid News: New Program Brings Ketamine-Assisted Psychotherapy To Canadian Vets
October 7, 2020
Forbes: Psychedelic Therapy Company, Field Trip Health, Goes Public To Revolutionize Mental Health Treatments
October 6, 2020
Benzinga: Field Trip Health Begins Trading On CSE
October 6, 2020
Canadian Securities Exchange: Field Trip Health (CSE:FTRP) Opens The Stock Market | Canadian Securities Exchange
October 5, 2020
Psychedelic Stock Watch: Field Trip RTO Provides Exciting New Investing Option
October 2, 2020
Business Insider: Field Trip Health Ltd. Completes Reverse Takeover Transaction And Prepares For Listing On CSE
September 29, 2020
Biotuesdays: Field Trip Completes GLP Synthesis Of FT-104
September 29, 2020
Psilocybin Alpha: Field Trip Announces Successful GLP Synthesis Results From Initial Preclinical Testing For FT-104, Its First Molecule In Development